AbbVie ends 11-year Calico partnership focused on aging research
FierceBiotech - 12-Nov-2025AbbVie ends its $1.75B Calico deal after the ALS drug fosigotifator failed in phase 2/3 trials
Join the club for FREE to access the whole archive and other member benefits.
Combating aging and associated diseases. An Alphabet (Google) subsidiary.
Founded in 2013 by Bill Maris.
Calico is a research and development company whose mission is to harness advanced technologies to increase our understanding of the biology that controls lifespan. We will use that knowledge to devise interventions that enable people to lead longer and healthier lives. Executing on this mission will require an unprecedented level of interdisciplinary effort and a long-term focus for which funding is already in place.
Chief scientist, David Botstein, retired late 2022.
Visit website: https://www.calicolabs.com/
Details last updated 04-Feb-2019
AbbVie ends its $1.75B Calico deal after the ALS drug fosigotifator failed in phase 2/3 trials
Genetic differences only change how strong the results are, not whether they work
Alphabet's Calico licenses IL-11 drug to target age-related diseases beyond China
AI startup decodes live cell behaviour using simple imaging and machine learning
Nellie is free, easy to use, and performs better than other tracking methods
Global dynamic model of transcriptional regulation in budding yeast